Cadence Capital Management’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Cadence Capital Management’s Portfolio KYTH Stock Details KYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-16,903	Closed	-$649K	–	626
2014 Q2	$649K	Buy	16,903 +5,103	+43%	+$178K	0.03%	464
2014 Q1	$469K	Buy	+11,800	New	+$528K	0.02%	528

Other funds holding KYTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Cadence Capital Management's KYTH Position: Q3 2014 in Review

Cadence Capital Management sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q3 2014, closing a stake of 16,903 shares — an estimated $649K sold.

Cadence Capital Management first reported a position in KYTH in Q1 2014 and held it in 2 quarters. The position peaked at $649K in Q2 2014. 110 funds tracked by Wall St. Rank hold KYTH as of Q3 2014.

Cadence Capital Management reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q3 2014 after selling out during the quarter.
Cadence Capital Management sold 16,903 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q3 2014, an estimated $649K.
Cadence Capital Management first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q1 2014 and held it in 2 quarters.
Cadence Capital Management's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $649K in Q2 2014.
110 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q3 2014.

Based on Cadence Capital Management's 13F filing for Q3 2014, filed 3 Nov 2014.